Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Great Place to Work® and Fortune magazine selected Rockwell Medical for the 2024 Fortune Best Workplaces in Manufacturing and ProductionTM List in the small & medium category.

"It is an honor for Rockwell Medical to be named one of the best companies to work for in the country," said Lesley Spriggs, Vice President of Human Resources at Rockwell Medical. "We have great leaders who care about each and every employee. I am incredibly proud of the talented team we have d at Rockwell Medical and am grateful for their continued commitment and dedication to manufacturing and delivering life-sustaining dialysis solutions to vulnerable patients with end-stage kidney disease."

About Fortune

Fortune upholds a legacy of award-winning writing and trusted reporting for executives who want to make business better. Independently owned, with a global perspective and digital agility, Fortune tells the stories of a new generation of innovators, builders, and risk takers. Online and in print, Fortune measures corporate performance through rigorous benchmarks and holds companies accountable. Fortune creates communities by convening true thought leaders and iconoclasts — those who shape industry, commerce, and society – through powerful and prestigious lists, events, and conferences, such as the iconic Fortune 500, the CEO Initiative, and Most Powerful Women. For more information, visit fortune.com.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023 and 2024 and named Fortune Best Workplaces in Manufacturing & ProductionTM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.rockwellmed.com.

Heather R. Hunter SVP, Chief Corporate Affairs Officer (248) 432-1362 IR@RockwellMed.com

Rockwell Medical (NASDAQ:RMTI)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 Rockwell Medical 차트를 더 보려면 여기를 클릭.
Rockwell Medical (NASDAQ:RMTI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 Rockwell Medical 차트를 더 보려면 여기를 클릭.